摘要
背景:很少有正常脑脊液(CSF)生物标志物谱的患者符合阿尔茨海默病(AD)的临床标准。 目的:本研究的目的是检验这些患者误诊的假设。 方法:来自e-PLM中心的患者满足由于AD(AD-MCI)引起的可能的AD痴呆或轻度认知障碍的核心临床标准,具有正常的CSFAβ1-42,T-tau和P-tau生物标志物以及临床随访包括在内。临床和影像学资料由独立委员会从基线(访问临床评估和CSF分析)到随访结束时进行复查,以作最终诊断。 结果:在1098例AD患者的脑脊液分析的e-PLM队列中,37例(3.3%)患者(20例AD痴呆核心临床标准,17例AD-MCI核心临床标准)脑脊液生物标志物谱正常,向上。所有患者均出现情景记忆障碍,27例(73%)患者在MRI扫描时出现内侧颞叶萎缩。中位随访36个月(范围7-74)后,最终诊断为AD MCI或9例(24%)患者的痴呆,并且由于28例(76%)患者的AD而不太可能。 18例(49%)患者(情绪障碍,非AD退行性痴呆,血管性认知功能障碍,酒精认知障碍,颞叶癫痫和海马硬化)纠正了误诊,10例(27%)患者的认知障碍未确定 结论:具有正常脑脊液生物标志物的AD诊断(MCI或痴呆)是一种罕见的病症。 特别建议临床随访考虑替代诊断。
关键词: 阿尔茨海默病,痴呆,轻度认知障碍,生物标志物,脑脊液,血管性痴呆,额颞叶痴呆,抑郁症。
Current Alzheimer Research
Title:Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Volume: 15 Issue: 7
关键词: 阿尔茨海默病,痴呆,轻度认知障碍,生物标志物,脑脊液,血管性痴呆,额颞叶痴呆,抑郁症。
摘要: Background: Few patients with a normal cerebrospinal fluid (CSF) biomarker profile fulfill the clinical criteria for Alzheimer disease (AD).
Objective: The aim of this study was to test the hypothesis of misdiagnoses for these patients.
Method: Patients from the e-PLM centers fulfilling the core clinical criteria for probable AD dementia or mild cognitive impairment due to AD (AD-MCI), with normal CSF Aβ1-42, T-tau and P-tau biomarkers and clinical follow-up, were included. Clinical and imaging data were reviewed by an independent board, from baseline (visit with clinical evaluation and CSF analysis) to the end of the follow-up, for a final diagnosis.
Results: In the e-PLM cohort of 1098 AD patients with CSF analysis, 37 (3.3%) patients (20 with AD dementia core clinical criteria and 17 with AD-MCI core clinical criteria) had normal CSF biomarker profile and a clinical follow-up. All patients presented with episodic memory impairment and 27 (73%) had medial temporal lobe atrophy on MRI-scan. After a median follow-up of 36 months (range 7-74), the final diagnosis was AD MCI or dementia for 9 (24%) patients, and unlikely due to AD for 28 (76%) patients. A misdiagnosis was corrected in 18 (49%) patients (mood disorders, non-AD degenerative dementia, vascular cognitive impairment, alcohol cognitive disorders, temporal epilepsy and hippocampal sclerosis), and 10 (27%) patients had cognitive disorders of undetermined etiology.
Conclusion: AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition. A clinical follow- up is particularly recommended to consider an alternative diagnosis.
Export Options
About this article
Cite this article as:
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers, Current Alzheimer Research 2018; 15 (7) . https://dx.doi.org/10.2174/1567205015666180110113238
DOI https://dx.doi.org/10.2174/1567205015666180110113238 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Lamotrigine Pharmacokinetics During Anticonception and Pregnancy
Letters in Drug Design & Discovery Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part I (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Structure Activity Relationships of Novel Antiepileptic Drugs
Current Medicinal Chemistry Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets The Role of Calcium Stores in Apoptosis and Autophagy
Current Molecular Medicine Metabotropic Glutamate Receptors Modulate Periaqueductal Grey Descending Analgesic System
Central Nervous System Agents in Medicinal Chemistry Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats
Current Alzheimer Research The Muscular Dystrophies Associated with Central Nervous System Lesions: A Brief Review from a Standpoint of the Localization and Function of Causative Genes
Current Pediatric Reviews PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism α7-Nicotinic Receptors and Cognition
Current Drug Targets Applications of Nuclear Technique to Biological Sciences Labelled Compounds, Radioactive Tracers, and X-Ray Tomography
Current Topics in Medicinal Chemistry New Insights in Prolactin Releasing Peptide (Prrp) in the Brain
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry Central Anti-Cholinergic Syndrome Induced by Single Therapeutic Dose of Atropine
Current Drug Safety Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued)